1. A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments

3. Description of Program

4. This program will include a discussion of investigational agents not approved by the FDA for use in the US.

5. Overview of Pemphigus Vulgaris

6. Pemphigus: Autoimmune Blistering Diseases

7. PV: Presentation

8. PV: Variants

9. PV: Clinical Signs and Complications

10. PV Is an Autoimmune Disease

11. PV: Health-Related Quality of Life

12. Pemphigus: Risk Factors for Hospitalization

13. Summary

14. A Closer Look at Pemphigus Vulgaris: Diagnosis and Disease Severity Assessment

15. Red Flags for Pemphigus Vulgaris

16. Differential Diagnosis: Ulcers of the Oropharyngeal Mucosa

17. Differential Diagnosis: Widespread Erosions

18. Differential Diagnosis: Tense Blisters

19. Laboratory Investigations: Biopsy
Content no longer available

20. Further Laboratory Investigations

21. Other Investigations to Pursue Before Treatment

22. Other Investigations to Pursue Before Treatment (cont)

23. Assessing Disease Severity

24. Monitoring Treatment Response

25. Monitoring by Primary Care Provider

26. Individualize Follow-up to the Patient

27. Predicting Risk of Relapse

28. Pemphigus Vulgaris: Current Treatment and Treatment Goals

29. Treatment Goals for Patients with PV

30. Corticosteroid Treatment

31. Initial High-Dose Treatment Required

32. Mechanism of Action of High-Dose Steroids

33. Steroid-Sparing Adjuvant Therapies

34. Grando Protocol for All Patients with PV

35. Grando Protocol: Example with Rituximab

36. Grando Protocol: Protect Skin

37. Grando Protocol: Oral or Esophageal Erosions

38. Duration of Therapy Before Remission

39. Rituximab and Other Adjuvant Therapies

40. Additional Comments

41. Emerging Treatments for Pemphigus Vulgaris

42. Many Treatment Strategies Focus on Suppressing the Immune Response

43. PEMPHIX Trial

44. Rituximab for PV: Recent Reports

45. Unanswered Questions About Rituximab

46. Ritux 3 Trial: Design

47. Ritux 3 Trial: Results

48. CAAR T Cells

49. PRN1008

50. SYNT1001

51. Polyclonal Regulatory T Cells(Poly Tregs)

52. Summary

53. Abbreviations

54. Abbreviations (cont)